by BERKEN IPAlicia Alvarez-Berkenwald at Venice
Managing Partner Alicia Alvarez-Berkenwald is already in Venice to attend the first edition of the AIPPI Spring Meeting.
Looking forward to seeing friends and colleagues in this wonderful setting!
by BERKEN IPAlready registered to attend the 2023 INTA Annual Meeting in Singapore?
If so, our Partners Lucía Scarpati, Vice Chair of INTA´s Brands and Innovation Committee, and María Aurora García, member of INTA’s Brands for a Better Society Committee, will be delighted to meet up with you at the conference.
To schedule a meeting with them, please contact us at [email protected].
by Diego Federico MartinPatentability of polymorphs in Argentina: some thoughts in the light of recent rulings
On December 16, 2021, and May 3, 2022, Division I of the Argentine Federal Court in Civil and Commercial matters rendered two separate rulings – PFIZER PRODUCTS INC v. INPI, Case No. 3753/2016, and BAYER CROPSCIENCE AG v. INPI, Case No. 5631/2015, respectively – which are thematically associated, since both refer to the patentability of polymorphs. Both rulings are the result of different lawsuits filed by the applicants of two patent applications that were rejected by the Argentina’s National Institute of Industrial Property (INPI), seeking to reverse the corresponding rejection decisions. Even though the rulings at issue rule that the controverted decision must be upheld, it is interesting to analyze the arguments set forth therein.
In both rulings, even though the arguments raised differ in certain aspects, the courts essentially held that the arguments set out by the appellant, just as the technical expert evidence produced ex officio, fail to undermine the conclusions of the INPI’s Examiner appointed for each application, which in both cases can be summarized in: (i) a lack of novelty (and inventive activity in the case of Case No. 5631/2015) of the claimed matter in view of a document of the previous art that discloses the “base” chemical compound (that is, the compound as it was initially synthesized, without having the crystalline form of the polymorph claimed in each application); and (ii) the characterization of the polymorphs as a discovery, a matter that is not patentable pursuant to Article 6 of Law No. 24481.
In the first place, it is worth reviewing briefly what a polymorph is. The molecules of a solid chemical compound can adopt one or more stable and organized spatial dispositions that result in structures known as “crystalline”. When a crystalline compound can adopt more than one distinctive crystalline structure, these are known as polymorphs.
When a new chemical compound is synthesized, it is common to obtain that compound with a certain crystalline structure. However, what cannot be predicted beforehand is whether the new compound will show polymorphism. The obtention of new crystalline forms of an already known compound will often involve laborious research programs, since finding the specific conditions for the generation of a new crystalline form may be a difficult task.
The different polymorphs of a chemical compound usually have different physicochemical properties, which could make a particular polymorph preferable over another, for instance, when formulating a medication comprising the chemical compound at issue. As a result of such advantageous properties, it may be convenient to obtain protection for a new polymorph by means of a patent.
The Patentability Guidelines used by the INPI’s Examiners to examine patent applications clearly set a negative criterion with regards to the patentability of polymorphs. In this sense, in the section known as “GUIDELINES FOR THE PATENTABILITY EXAMINATION OF PATENT APPLICATIONS ABOUT CHEMICAL-PHARMACEUTICAL INVENTIONS” (from now on, “the Guidelines”), in the subsection associated specifically to polymorphs, the following is mentioned:
“Polymorphism is a property inherent to the solid form exhibited by drugs used in the pharmaceutical industry (active principles and excipients).
That is, it is not a man-made invention but a property of the substance instead.”
Said subsection concludes that:
“1. As long as claims about polymorphs stem from the mere identification and/or characterization of a new crystalline form of a substance that is already known in the state of the art, even when they show pharmacokinetic or stability differences with regards to the already known solid forms (amorphous and/or crystalline) of the same substance, such claims are not admissible.
2. The processes used to obtain polymorphs constitute a routine experimentation in the preparation of drugs; they are not patentable because trying to obtain the pharmaceutically most adequate polymorph by means of conventional methods is evident.”
That is, according to what is described in the Guidelines, a polymorph would not be an invention, instead, it would be the discovery of an inherent property of a substance that was previously known and, consequently, not patentable. Furthermore, the processes used to obtain polymorphs would lack inventive activity in a general manner, a reason for which they would not be patentable either.
Considering what was analyzed in the previous paragraphs, two aspects of the rulings at issue are particularly remarkable.
On the one hand, it is worth noticing that in both administrative procedures the Examiner of each application has raised not only an objection of exclusion from patentability of the discoveries, which, while being debatable, turns out to be consistent with what is established in the Guidelines, but also an objection of lack of novelty, when the documents of the previous art already mentioned do not disclose the claimed polymorph in each case (it is worth highlighting that in both cases the cited document belongs to the same applicant as that of the application in controversy, therefore, it is to be expected for said applicant to perfectly know that they have actually obtained a previously unknown polymorph). The INPI seems to construe that the disclosure of a chemical compound leads to, implicitly, the disclosure of any crystalline form thereof.
On the other hand, we consider it relevant that in both cases the court sets out the inability of the arguments set forth and, in particular, of the court’s technical expert evidence produced ex officio, to disqualify the technical opinion of the Examiner of each application, mentioning that a mere contrary opinion is not sufficient, and that, instead, it must be shown that the Examiner incurred in an error in the assessment of the claimed matter. Thus, when posing questions to a court appointed expert in a litigation that seeks to reverse a rejection decision from the INPI, such questions must be posed in such a way that the alleged errors identified in the manner in which the Examiner examined the application come to light. In this sense, it is of great importance to develop an appropriate strategy.
Our experts are available to debate protection and litigation strategies in line with the needs of each inventor or patent applicant.
by BERKEN IPASIPI Meeting 2022
Our Partners Alicia Alvarez Berkenwald and María Aurora García will participate in ASIPI’s XXIII Jornadas de Trabajo y Consejo de Administración that will take place in Medellín on December 04 to 07, 2022.
“The city of eternal spring” and cradle of innovation, is the ideal setting to meet up with friends and colleagues.
by BERKEN IPINTA’s Leadership Meeting at Miami
Our Partners Lucía Scarpati, Vice Chair of INTA´s Brands and Innovation Committee, and MARIA AURORA GARCIA, member of INTA’s Brands for a Better Society Committee, will be in Miami next week for INTA’s Leadership Meeting.
To meet up with them, please contact us at [email protected].
by BERKEN IPEmilio Berkenwald at AIPLA 2022
Partner Emilio Berkenwald attends the 2022 AIPLA Annual Meeting in National Harbor, MD. This year, AIPLA celebrates 125 years!
#intellectualproperty #patents #patentlaw
by BERKEN IP2022 FICPI World Congress
Pleasure and work get together in Cannes!
#FICPI #intellectualproperty #patents #patentlaw
by BERKEN IP2022 AIPPI World Congress
San Francisco was a beautiful venue for going back to in-person meetings!
#AIPPI #intellectualproperty #patents #bayarea #congress
by BERKEN IP2022 FICPI World Congress
The 2022 FICPI World Congress is Cannes is coming up soon and our partners in attendance Alicia Alvarez-Berkenwald, María Aurora García and Emilio Berkenwald are very much looking forward to reconnecting with friends and colleagues in this wonderful venue.
If you are interested in meeting with them, please send us an email to [email protected] indicating your availability and we will be glad set up an appointment.
#FICPI #intellectualproperty #patents #patentlaw
by BERKEN IP2022 AIPPI World Congress
The 2022 AIPPI World Congress is fast approaching and our partners in attendance Alicia Alvarez-Berkenwald, Federico Ulled and Emilio Berkenwald are very much looking forward to this great opportunity to reconnect with friends and colleagues.
If you are interested in meeting with them, please send us an email to [email protected] indicating your availability and we will be glad set up an appointment.